Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for lung scarring: ABBV-142 enters Mid-Stage trial

NCT ID NCT07230288

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 04, 2026 · Updated 6 times

Summary

This study tests an experimental drug called ABBV-142 in people with idiopathic pulmonary fibrosis (IPF), a rare lung disease that causes scarring and breathing problems. About 165 adults will receive either ABBV-142 or a placebo for 52 weeks to see if the drug is safe and can help preserve lung function. The trial is double-blind, meaning neither participants nor doctors know who gets the real drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ABBV-142
What this could lead to
If successful, this could point toward a new treatment option to slow lung function decline in people with idiopathic pulmonary fibrosis.
What could go wrong
This is an early Phase 2a study with a small sample size, so results may not confirm effectiveness. The drug is investigational and may cause side effects or fail to improve lung function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 165 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Diagnosis of Idiopathic Pulmonary Fibrosis (IPF) within 7 years prior to screening, confirmed by the investigator at screening that is supported by centrally read chest high-resolution computed tomography (HRCT) obtained within 12 months of the screening visit and verification of usual interstitial pneumonia(UIP) or probable UIP. Exclusion Criteria: * History of stroke within 6 months prior to screening * In the opinion of the investigator, other clinically significant pulmonary abnormalities * History of any malignancy up to 5 years prior screening visit, except for successfully treated nonmelanoma skin cancer or localized carcinoma in situ of the cervix.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic pulmonary fibrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Idiopathic pulmonary fibrosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    57 sites in 17 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Acibadem City Clinic Tokuda University Hospital EAD /ID# 277846

    RECRUITING

    Sofia, 1407, Bulgaria

  • Caritas-Krankenhaus St. Maria gGmbH /ID# 278138

    RECRUITING

    Donaustauf, Bavaria, 93093, Germany

  • Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou /ID# 278333

    RECRUITING

    Rennes, Ille-et-Vilaine, 35033, France

  • Centre d'Investigation Clinique Mauricie /ID# 277949

    RECRUITING

    Trois-Rivières, Quebec, G8T 7A1, Canada

  • China Medical University Hospital /ID# 278039

    RECRUITING

    Taichung, 40447, Taiwan

  • Christie Clinic on University /ID# 277871

    RECRUITING

    Champaign, Illinois, 61820, United States

  • Clinical Research Specialists - Kissimmee /ID# 279184

    RECRUITING

    Kissimmee, Florida, 34746, United States

  • Diagnostic Consultative Center Convex /ID# 277848

    RECRUITING

    Sofia, 1680, Bulgaria

  • Diagnostic Consultative Center Convex /ID# 277849

    RECRUITING

    Sofia, 1680, Bulgaria

  • Dr Hannes J van Rensburg inc /ID# 278278

    RECRUITING

    Cape Town, Western Cape, 7130, South Africa

  • Dr JM Engelbrecht Trial Site /ID# 278287

    RECRUITING

    Somerset West, Western Cape, 7130, South Africa

  • Eastern Health /ID# 278245

    RECRUITING

    Box Hill, Victoria, 3128, Australia

  • Edinburgh Royal Infirmary - NHS Lothian /ID# 278631

    RECRUITING

    Edinburgh, Edinburgh, City of, EH16 4SA, United Kingdom

  • General Hospital of Chest Diseases of Athens SOTIRIA /ID# 277724

    RECRUITING

    Athens, Attica, 11527, Greece

  • General Hospital of Thessaloniki George Papanikolaou /ID# 277819

    RECRUITING

    Thessaloniki, 57010, Greece

  • Gulhane Egitim ve Arastirma Hastanesi /ID# 278944

    RECRUITING

    Ankara, Antalya, 06010, Turkey (Türkiye)

  • Hannibal Regional Hospital /ID# 277984

    RECRUITING

    Hannibal, Missouri, 63401, United States

  • Henry Ford Hospital /ID# 277843

    RECRUITING

    Detroit, Michigan, 48202, United States

  • Hopital Arnaud de Villeneuve /ID# 278322

    RECRUITING

    Montpellier, Herault, 34090, France

  • Hopital Avicenne /ID# 279212

    RECRUITING

    Bobigny, Île-de-France Region, 93000, France

  • Hospital Clinico Universitario de Valencia /ID# 277921

    RECRUITING

    Valencia, 46010, Spain

  • Hospital Universitari i Politecnic La Fe /ID# 278478

    RECRUITING

    Valencia, 46026, Spain

  • Inje University Haeundae Paik Hospital /ID# 278000

    RECRUITING

    Busan, Busan Gwang Yeogsi, 48108, South Korea

  • Inova Fairfax Hospital /ID# 278469

    RECRUITING

    Falls Church, Virginia, 22042, United States

  • Institute For Pulmonary Diseases Of Vojvodina /ID# 278499

    RECRUITING

    Kamenitz, Sremski Okrug, 21208, Serbia

  • Jefferson Health Honickman Center /ID# 279127

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

  • Kaohsiung Chang Gung Memorial Hospital /ID# 278043

    RECRUITING

    Kaohsiung City, 833, Taiwan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 278029

    RECRUITING

    Kaohsiung City, 807, Taiwan

  • Klinikum Konstanz /ID# 278139

    RECRUITING

    Konstanz, Baden-Wurttemberg, 78464, Germany

  • Linkou Chang Gung Memorial Hospital /ID# 278042

    RECRUITING

    Taoyuan City, 333, Taiwan

  • Lung Research Queensland /ID# 278838

    RECRUITING

    Nundah, Queensland, 4012, Australia

  • Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 278943

    RECRUITING

    Istanbul, 34899, Turkey (Türkiye)

  • NHO Kinki Chuo Chest Medical Center /ID# 280225

    RECRUITING

    Sakai-shi, Osaka, 591-8555, Japan

  • National Taiwan University Hospital /ID# 278041

    RECRUITING

    Taipei, 100, Taiwan

  • Norfolk and Norwich University Hospital /ID# 278224

    RECRUITING

    Norwich, Norfolk, NR4 7UY, United Kingdom

  • Royal Brompton Hospital /ID# 278007

    RECRUITING

    London, Greater London, SW3 6NP, United Kingdom

  • Royal Papworth Hospital NHS Foundation Trust /ID# 278055

    RECRUITING

    Cambridge, Cambridgeshire, CB2 0AY, United Kingdom

  • Sec Clinical Research - East - Dothan - Graceland /ID# 278328

    RECRUITING

    Dothan, Alabama, 36305, United States

  • Seoul National University Bundang Hospital /ID# 278059

    RECRUITING

    Seongnam-si, Gyeonggido, 13620, South Korea

  • Taipei Veterans General Hospital /ID# 278038

    RECRUITING

    Taipei, 112, Taiwan

  • The Catholic University Of Korea, Bucheon St. Mary'S Hospital /ID# 278068

    RECRUITING

    Bucheon-si, Gyeonggido, 14647, South Korea

  • The University of Alabama at Birmingham /ID# 277613

    RECRUITING

    Birmingham, Alabama, 35233, United States

  • UCLH NHS FT - University College Hospital /ID# 279198

    RECRUITING

    London, Greater London, NW1 2BU, United Kingdom

  • Unidade Local de Saude de Loures-Odivelas-Hospital Beatriz Angelo /ID# 278357

    RECRUITING

    Loures, Lisbon District, 2674-514, Portugal

  • Unidade Local de Saude de Matosinhos EPE /ID# 277980

    RECRUITING

    Senhora da Hora, Porto District, 4464-513, Portugal

  • Unidade Local de Saude do Algarve, EPE /ID# 278388

    RECRUITING

    Faro, 8000-386, Portugal

  • University Clinical Center Serbia /ID# 278496

    RECRUITING

    Belgrade, Beograd, 11000, Serbia

  • University General Hospital of Heraklion /ID# 277717

    RECRUITING

    Heraklion, Crete, 71500, Greece

  • University General Hospital of Patras /ID# 277726

    RECRUITING

    Pátrai, Achaia, 26504, Greece

  • University Hospital Southampton /ID# 278223

    RECRUITING

    Southampton, Hampshire, SO16 6YD, United Kingdom

  • University Hospital of Ioannina /ID# 277719

    RECRUITING

    Ioannina, 45500, Greece

  • University Multiprofile Hospital For Active Treatment Sveti Georgi - Plovdiv /ID# 279367

    RECRUITING

    Plovdiv, 4002, Bulgaria

  • University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski /ID# 277845

    RECRUITING

    Pleven, 5800, Bulgaria

  • University of Michigan Health System - Ann Arbor /ID# 279994

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • Virginia Commonwealth University Medical Center /ID# 277992

    RECRUITING

    Richmond, Virginia, 23219, United States

  • Vitamed Galaj i Cichomski Sp.j. /ID# 278145

    RECRUITING

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-079, Poland

  • Yonsei University Health System Severance Hospital /ID# 278166

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.